Gadolinium-enhanced cardiovascular magnetic resonance and exercise capacity in hypertrophic cardiomyopathy;Cardiorresonancia magnética con gadolinio y capacidad de esfuerzo en la miocardiopatía hipertrófica

Revista Espanola de Cardiologia

Volumn 61, Issue 8, 2008, Pages 853-860

  Romero Puche, Antonio ^a   Marín, Francisco ^a   González Carrillo, Josefa ^a   García Honrubia, Antonio ^b   Climent, Vicente ^b   Feliu, Eloisa ^b   Ruiz Espejo, Francisco ^a   Payá, Eduardo ^b   Gimeno Blanes, Juan R ^a   De La Morena, Gonzalo ^a   Valdés Chavarri, Mariano ^a  

^a HOSPITAL UNIVERSITARIO VIRGEN DE LA ARRIXACA   (Spain)

^b HOSPITAL GENERAL UNIVERSITARIO DE ALICANTE   (Spain)

Author keywords

Exercise; Fibrosis; Hypertrophic cardiomyopathy; Late contrast enhancement; Magnetic resonance imaging

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; GADOLINIUM;

ADULT; ARTICLE; CLINICAL ASSESSMENT; CONTROLLED STUDY; DOPPLER ECHOCARDIOGRAPHY; EXERCISE; EXERCISE TEST; FEMALE; FUNCTIONAL STATUS; HEART ATRIUM FIBRILLATION; HEART MUSCLE FIBROSIS; HOLTER MONITORING; HUMAN; HYPERTROPHIC CARDIOMYOPATHY; IMAGE ENHANCEMENT; MAJOR CLINICAL STUDY; MALE; NUCLEAR MAGNETIC RESONANCE;

EID: 49449104959     PISSN: 03008932     EISSN: 15792242     Source Type: Journal    
DOI: 10.1157/13124996     Document Type: Article

References (27)

1. Varnava AM, Elliott PM, Sharma S, McKenna WJ, Davies MJ. Hypertrophic cardiomyopathy: the interrelation of disarray, fibrosis, and small vessel disease. Heart. 2000;84:476-82.
2. Maron BJ, Olivotto I, Bellone P, Conte MR, Cecchi F, Flygenring BP, et al. Clinical profile of stroke in 900 patients with hypertrophic cardiomyopathy. J Am Coll Cardiol. 2002;39:301-7.
3. Elliott PM, Poloniecki J, Dickie S, Sharma S, Monserrat L, Varnava A, et al. Sudden death in hypertrophic cardiomyopathy: Identification of high risk patients. J Am Coll Cardiol. 2000;36:2212-8.
4. Maron BJ, McKenna WJ, Danielson GK, Kappenberger LJ, Kuhn HJ, Seidman CE, et al. American College of Cardiology/European Society of Cardiology Clinical Expert Consensus Document on Hypertrophic Cardiomyopathy. A report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the European Society of Cardiology Committee for Practice Guidelines. Eur Heart J. 2003;24:1965-91.
5. Monserrat L, Elliott PM, Gimeno JR, Sharma S, Penas-Lado M, McKenna WJ. Non-sustained ventricular tachycardia in hypertrophic cardiomyopathy: an independent marker of sudden death risk in young patients. J Am Coll Cardiol. 2003;42:873-9.
6. Spirito P, Maron BJ, Bonow RO, Epstein SE. Severe functional limitation in patients with hypertrophic cardiomyopathy and only mild localized left ventricular hypertrophy. J Am Coll Cardiol. 1986;8:537-44.
7. Maron BJ, Tholakanahalli VN, Zenovich AG, Casey SA, Duprez D, Aeppli DM, et al. Usefulness of B-type natriuretic peptide assay in the assessment of symptomatic state in hypertrophic cardiomyopathy. Circulation. 2004;109:984-9.
8. Thaman R, Esteban MT, Barnes S, Gimeno JR, Mist B, Murphy R, et al. Usefulness of N-terminal pro-B-type natriuretic peptide levels to predict exercise capacity in hypertrophic cardiomyopathy. Am J Cardiol. 2006;98:515-9.
9. Choudhury L, Mahrholdt H, Wagner A, Choi KM, Elliott MD, Klocke FJ, et al. Myocardial scarring in asymptomatic or mildly symptomatic patients with hypertrophic cardiomyopathy. J Am Coll Cardiol. 2002;40:2156-64.
10. Dumont CA, Monserrat L, Soler R, Rodríguez E, Fernández X, Peteiro J, et al. Significado clínico del realce tardío de gadolinio con resonancia magnética en pacientes con miocardiopatía hipertrófica. Rev Esp Cardiol. 2007;60:15-23.
11. Moon JC, McKenna WJ, McCrohon JA, Elliott PM, Smith GC, Pennell DJ. Toward clinical risk assessment in hypertrophic cardiomyopathy with gadolinium cardiovascular magnetic resonance. J Am Coll Cardiol. 2003;41:1561-7.
12. Moon JC, Mogensen J, Elliott PM, Smith GC, Elkington AG, Prasad SK, et al. Myocardial late gadolinium enhancement cardiovascular magnetic resonance in hypertrophic cardiomyopathy caused by mutations in troponin I. Heart. 2005;91:1036-40.
13. Moon JC, Reed E, Sheppard MN, Elkington AG, Ho SY, Burke M, et al. The histologic basis of late gadolinium enhancement cardiovascular magnetic resonance in hypertrophic cardiomyopathy. J Am Coll Cardiol. 2004;43:2260-4.
14. Pujadas S, Carreras F, Arrastio X, Leta R, Vila M, Subirana MT, et al. Detección y cuantificación de la fibrosis miocárdica en la miocardiopatía hipertrófica mediante cardiorresonancia magnética con contraste. Rev Esp Cardiol. 2007;60:10-4.
15. Kim RJ, Fieno DS, Parrish TB, Harris K, Chen EL, Simonetti O, et al. Relationship of MRI delayed contrast enhancement to irreversible injury, infarct age, and contractile function. Circulation. 1999;100:1992-2002.
16. Moon JC. ¿Qué significa la captación tardía de gadolinio en la miocardiopatía hipertrófica? Rev Esp Cardiol. 2007;60:1-4.
17. McKenna WJ, Spirito P, Desnos M, Dubourg O, Komajda M. Experience from clinical genetics in hypertrophic cardiomyopathy: proposal for new diagnostic criteria in adult members of affected families. Heart. 1997;77:130-2.
18. Counihan PJ, Frenneaux MP, Webb DJ, McKenna WJ. Abnormal vascular responses to supine exercise in hypertrophic cardiomyopathy. Circulation. 1991;84:686-96.
19. De la Morena Valenzuela G, Florenciano Sánchez R, García Almagro FJ, González Caballero E, Pascual Figal D, Soria Arcos F, et al. Evaluación funcional de los pacientes con miocardiopatía hipertrófica mediante análisis del consumo de oxígeno máximo. Rev Esp Cardiol. 2003;56:865-72.
20. Elliott PM, Gimeno Blanes JR, Mahon NG, Poloniecki JD, McKenna WJ. Relation between severity of left-ventricular hypertrophy and prognosis in patients with hypertrophic cardiomyopathy. Lancet. 2001;357:420-4.
21. Kofflard MJ, Ten Cate FJ, Van der Lee C, Van Domburg RT. Hypertrophic cardiomyopathy in a large community-based population: clinical outcome and identification of risk factors for sudden cardiac death and clinical deterioration. J Am Coll Cardiol. 2003;41:987-93.
22. Maron BJ, Spirito P. Implications of left ventricular remodeling in hypertrophic cardiomyopathy. Am J Cardiol. 1998;81:1339-44.
23. Maron MS, Olivotto I, Betocchi S, Casey SA, Lesser JR, Losi MA, et al. Effect of left ventricular outflow tract obstruction on clinical outcome in hypertrophic cardiomyopathy. N Engl J Med. 2003;348:295-303.
24. Thaman R, Gimeno JR, Murphy RT, Kubo T, Sachdev B, Mogensen J, et al. Prevalence and clinical significance of systolic impairment in hypertrophic cardiomyopathy. Heart. 2005;91:920-5.
25. Varnava AM, Elliott PM, Mahon N, Davies MJ, McKenna WJ. Relation between myocyte disarray and outcome in hypertrophic cardiomyopathy. Am J Cardiol. 2001;88:275-9.
26. Sipola P, Peuhkurinen K, Lauerma K, Husso M, Jaaskelainen P, Laakso M, et al. Myocardial late gadolinium enhancement is associated with raised serum amino-terminal propeptide of type III collagen concentrations in patients with hypertrophic cardiomyopathy attributable to the Asp175Asn mutation in the alpha tropomyosin gene: magnetic resonance imaging study. Heart. 2006;92:1321-2.
27. Sharma S, Elliott P, Whyte G, Jones S, Mahon N, Whipp B, et al. Utility of cardiopulmonary exercise in the assessment of clinical determinants of functional capacity in hypertrophic cardiomyopathy. Am J Cardiol. 2000;86:162-8.